TD Cowen analyst Tyler Van Buren has maintained their bullish stance on RCKT stock, giving a Buy rating today.
Tyler Van Buren’s rating is based on the promising developments in Rocket Pharmaceuticals’ pipeline, particularly in their pivotal study for Danon Disease. The study has completed enrollment and is progressing with dosing, with an update expected in the first half of 2025. The high probability of success in this study, which represents a significant market opportunity, is a key factor in the Buy rating.
Additionally, the company’s advancements in their AAV pipeline, notably the RP-A601 program for PKP2-ACM, contribute to the positive outlook. This program has received orphan medicinal product designation and shows promising data, further supporting the Buy recommendation. The combination of these factors, alongside the expected resolution of regulatory issues and completion of key submissions, underpins the confidence in Rocket Pharmaceuticals’ future performance.